Background: Trichosporon species are rare but emerging opportunistic yeast pathogens in bloodstream infections, predominantly affecting immunocompromised patients. These infections are often associated with high mortality and morbidity rates. Purpose: To identify and determine the frequency, risk factors, and clinical outcomes of Trichosporon bloodstream infections; to evaluate antifungal susceptibility patterns; and to incorporate the European Confederation of Medical Mycology (ECMM) EQUAL score to assess the quality of clinical management. Materials and Methods: A retrospective study was conducted on patients with Trichosporon bloodstream infections from 1st January 2017 to 31st December 2024. Clinical characteristics, antifungal susceptibility testing, and ECMM EQUAL score assessments were analyzed to evaluate management quality and outcomes. Results: A total of 17 patients were diagnosed with Trichosporon bloodstream infection during the study period, of which 11isolates (64.71%) were identified as Trichosporon asahii, while 6 isolates (35.29%) remained unclassified at the species level. The median patient age was 55 years with a male predominance (70.59%). Antifungal susceptibility testing showed favorable in vitro activity for voriconazole, whereas intrinsic resistance to echinocandins was observed. The median EQUAL score was 18 (IQR: 12.5-20.5, range-06-25). The overall crude mortality rate was 52.94%. Conclusions: The EQUAL score was not associated with mortality but served as a useful tool to assess quality of management. Timely diagnosis and appropriate antifungal therapy, particularly with voriconazole, are critical for improving outcomes in Trichosporon bloodstream infections.